FactSet Survey Shows Capricor Therapeutics Rated as Buy with Average Price Target of $39.50

Summary

According to a FactSet survey, analysts have given Capricor Therapeutics an average rating of ‘Buy’ with an average price target of $39.50.Trading View

Impact Analysis

This event is classified at the company level as it pertains specifically to Capricor Therapeutics and its stock performance expectations. The ‘Buy’ rating and price target of $39.50 indicate positive sentiment from analysts, potentially influencing investor decisions and leading to stock price appreciation as expectations align with market behavior. Some references provide additional context on analyst ratings and price targets from other sources, e.g., HC Wainwright with a target of $77.00, Cantor Fitzgerald at $30.00, and Roth Capital at $31.00, which demonstrate varying degrees of optimism.Market Beat+ 2 These differences can create opportunities for investors to assess the potential upside relative to the consensus target. However, Wall Street Zen downgrading the stock to ‘Sell’ highlights a risk of conflicting views potentially leading to volatility.Market Beat